UK Markets open in 4 hrs 28 mins
  • NIKKEI 225

    27,377.44
    -395.46 (-1.42%)
     
  • HANG SENG

    24,778.51
    -173.84 (-0.70%)
     
  • CRUDE OIL

    86.29
    -0.61 (-0.70%)
     
  • GOLD FUTURES

    1,841.30
    -1.30 (-0.07%)
     
  • DOW

    34,715.39
    -313.21 (-0.89%)
     
  • BTC-GBP

    28,952.04
    -2,057.11 (-6.63%)
     
  • CMC Crypto 200

    925.56
    -69.70 (-7.00%)
     
  • Nasdaq

    14,154.02
    -186.28 (-1.30%)
     
  • ^FTAS

    4,274.52
    +0.73 (+0.02%)
     

Global Neuromyelitis Optica (Devic's Syndrome) Clinical Trials Market Research Report, H2 2021 Review - ResearchAndMarkets.com

·3-min read

DUBLIN, December 01, 2021--(BUSINESS WIRE)--The "Neuromyelitis Optica (Devic's Syndrome) - Global Clinical Trials Review, H2, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.

The clinical trial report provides an overview of Neuromyelitis Optica (Devic's Syndrome) Clinical trials scenario.

This report provides top line data relating to the clinical trials on Neuromyelitis Optica (Devic's Syndrome) . Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe.

The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Scope

  • The report provides a snapshot of the global clinical trials landscape

  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status

  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company

  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment

  • The Report provides enrollment trends for the past five years

  • Report provides latest news for the past three months

Key Topics Covered:

  • Report Guidance

  • Clinical Trials Report Coverage

  • Clinical Trials by Region

  • Clinical Trials and Average Enrollment by Country

  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific

  • Top Five Countries Contributing to Clinical Trials in Europe

  • Top Countries Contributing to Clinical Trials in North America

  • Top Five Countries Contributing to Clinical Trials in Middle East and Africa

  • Top Five Countries Contributing to Clinical Trials in Central and South America

  • Clinical Trials by G7 Countries: Proportion of Neuromyelitis Optica (Devic's Syndrome) to Central Nervous System Clinical Trials

  • Clinical Trials by Phase in G7 Countries

  • Clinical Trials in G7 Countries by Trial Status

  • Clinical Trials by E7 Countries: Proportion of Neuromyelitis Optica (Devic's Syndrome) to Central Nervous System Clinical Trials

  • Clinical Trials by Phase in E7 Countries

  • Clinical Trials in E7 Countries by Trial Status

  • Clinical Trials by Phase

  • In Progress Trials by Phase

  • Clinical Trials by Trial Status

  • Clinical Trials by End Point Status

  • Subjects Recruited Over a Period of Time

  • Clinical Trials by Sponsor Type

  • Prominent Sponsors

  • Top Companies Participating in Neuromyelitis Optica (Devic's Syndrome) Therapeutics Clinical Trials

  • Prominent Drugs

  • Clinical Trial Profile Snapshots

  • Appendix

Companies Mentioned

  • F. Hoffmann-La Roche Ltd

  • AstraZeneca Plc

  • The Lundbeck Foundation

  • Boston Pharmaceuticals Inc

  • Hbm Holdings Ltd

  • PPD Inc

  • Takeda Pharmaceutical Co Ltd

  • Yantai Rongchang Pharmaceutical Co Ltd

  • Bionure Farma SL

  • Pamplona Capital Management LLP

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/i33f8e

View source version on businesswire.com: https://www.businesswire.com/news/home/20211201005969/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting